交易 Sonoma Pharma - SNOA CFD
加入收藏夹- 概括
- 历史数据
- 活动
- 收入报表
- 资产负债表
- 现金流
- 所有权
价差 | - | ||||||||
多头隔夜费
Long position overnight fee
前往平台 | -0.025457% | ||||||||
空头隔夜费
Short position overnight fee
前往平台 | 0.003235% | ||||||||
隔夜费时间 | 21:00 (UTC) | ||||||||
最小交易量 | 1 | ||||||||
货币 | USD | ||||||||
保证金 | 20% | ||||||||
上市交易所 | United States of America | ||||||||
交易费 | 0% |
*Information provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | 平仓 | Change | Change (%) | 開倉 | High | Low |
---|
Sonoma Pharma Events
时间(协调世界时) (UTC) | 国家/地区 | 事件 |
---|---|---|
Tuesday, July 11, 2023 | ||
时间(协调世界时) (UTC) 20:00 | 国家/地区 US
| 事件 Q4 2023 Sonoma Pharmaceuticals Inc Earnings Release Q4 2023 Sonoma Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
Wednesday, August 9, 2023 | ||
时间(协调世界时) (UTC) 20:00 | 国家/地区 US
| 事件 Q1 2024 Sonoma Pharmaceuticals Inc Earnings Release Q1 2024 Sonoma Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
Friday, September 15, 2023 | ||
时间(协调世界时) (UTC) 20:00 | 国家/地区 US
| 事件 Sonoma Pharmaceuticals Inc Annual Shareholders Meeting Sonoma Pharmaceuticals Inc Annual Shareholders MeetingForecast -Previous - |
Monday, November 13, 2023 | ||
时间(协调世界时) (UTC) 21:00 | 国家/地区 US
| 事件 Q2 2024 Sonoma Pharmaceuticals Inc Earnings Release Q2 2024 Sonoma Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
总收入 | 12.628 | 18.629 | 17.928 | 18.97 | 16.658 |
收入 | 12.628 | 18.629 | 17.928 | 18.97 | 16.658 |
收入成本,共计 | 8.417 | 11.847 | 9.806 | 10.09 | 9.348 |
毛利 | 4.211 | 6.782 | 8.122 | 8.88 | 7.31 |
总营业费用 | 17.792 | 22.078 | 25.318 | 30.228 | 30.847 |
销售/一般/行政费用,总计 | 9.755 | 9.453 | 14.173 | 18.62 | 19.924 |
研究与开发 | 0.125 | 0.555 | 1.339 | 1.518 | 1.575 |
营业收入 | -5.164 | -3.449 | -7.39 | -11.258 | -14.189 |
利息收入(费用),非经营净值 | -0.01 | 0.004 | 0.034 | 0.157 | 0.218 |
其他,净值 | -0.394 | -0.594 | 0.24 | -0.239 | -0.307 |
税前净收入 | -5.418 | -3.902 | -3.544 | -11.34 | -14.278 |
税后净收入 | -5.086 | -4.615 | -3.573 | -11.798 | -14.328 |
未计算非常项目前的净收益 | -5.086 | -4.615 | -3.573 | -11.798 | -14.328 |
非常规项目总计 | 0 | 0.665 | 0.265 | ||
净收入 | -5.086 | -3.95 | -3.308 | -11.798 | -14.328 |
普通股股东可获收益 (不含非经常性项目) | -5.086 | -4.615 | -3.573 | -11.798 | -14.328 |
普通股股东可获收益 (含非經常性項目) | -5.086 | -3.95 | -3.308 | -11.798 | -14.328 |
摊薄净收入 | -5.086 | -3.95 | -3.308 | -11.798 | -14.328 |
摊薄后加权平均股 | 2.653 | 1.996 | 1.477 | 0.924 | 0.503 |
扣除特别项目的每股摊薄盈利 | -1.91708 | -2.31212 | -2.41909 | -12.7684 | -28.4851 |
每股正常摊薄盈利 | -2.07755 | -2.28412 | -3.99106 | -12.7684 | -28.4851 |
Gain (Loss) on Sale of Assets | 0.15 | 0.137 | 3.572 | ||
异常费用(收入) | -0.505 | 0.223 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
总收入 | 2.944 | 3.331 | 3.983 | 2.298 | 2.902 |
收入 | 2.944 | 3.331 | 3.983 | 2.298 | 2.902 |
收入成本,共计 | 2.102 | 1.999 | 2.32 | 2.222 | 1.685 |
毛利 | 0.842 | 1.332 | 1.663 | 0.076 | 1.217 |
总营业费用 | 4.778 | 4.062 | 4.838 | 4.635 | 3.86 |
销售/一般/行政费用,总计 | 2.665 | 2.067 | 2.295 | 3.152 | 2.135 |
研究与开发 | 0 | 0 | 0.006 | 0.004 | 0.026 |
异常费用(收入) | 0.011 | -0.004 | 0.217 | -0.743 | 0.014 |
营业收入 | -1.834 | -0.731 | -0.855 | -2.337 | -0.958 |
利息收入(费用),非经营净值 | 0.001 | 0.003 | 0 | -0.009 | 0.003 |
Gain (Loss) on Sale of Assets | 0.001 | 0 | 0 | 0 | |
其他,净值 | -0.073 | -0.189 | -0.067 | -0.936 | 0.011 |
税前净收入 | -1.905 | -0.917 | -0.922 | -3.282 | -0.944 |
税后净收入 | -1.939 | -1.017 | -0.887 | -2.944 | -0.944 |
未计算非常项目前的净收益 | -1.939 | -1.017 | -0.887 | -2.944 | -0.944 |
非常规项目总计 | 0 | 0 | |||
净收入 | -1.939 | -1.017 | -0.887 | -2.944 | -0.944 |
普通股股东可获收益 (不含非经常性项目) | -1.939 | -1.017 | -0.887 | -2.944 | -0.944 |
普通股股东可获收益 (含非經常性項目) | -1.939 | -1.017 | -0.887 | -2.944 | -0.944 |
摊薄净收入 | -1.939 | -1.017 | -0.887 | -2.944 | -0.944 |
摊薄后加权平均股 | 3.107 | 3.101 | 3.101 | 3.091 | 3.08 |
扣除特别项目的每股摊薄盈利 | -0.62407 | -0.32796 | -0.28604 | -0.95244 | -0.30649 |
每股正常摊薄盈利 | -0.62198 | -0.3288 | -0.24055 | -1.10869 | -0.30195 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
流动资产总额 | 16.43 | 12.983 | 12.283 | 12.496 | 16.254 |
现金和短期投资 | 7.396 | 4.22 | 3.691 | 3.689 | 10.066 |
现金等价物 | 7.396 | 4.22 | 3.691 | 3.689 | 10.066 |
应收账款总额,净额 | 4.778 | 4.656 | 5.278 | 4.444 | 1.752 |
Accounts Receivable - Trade, Net | 2.407 | 2.806 | 3.973 | 3.481 | 1.537 |
Total Inventory | 2.663 | 2.53 | 2.181 | 3.409 | 2.865 |
Prepaid Expenses | 1.375 | 1.368 | 0.951 | 0.731 | 1.332 |
Other Current Assets, Total | 0.218 | 0.209 | 0.182 | 0.223 | 0.239 |
Total Assets | 18.845 | 14.987 | 14.561 | 14.448 | 19.206 |
Property/Plant/Equipment, Total - Net | 0.879 | 1.129 | 0.724 | 0.727 | 1.136 |
Property/Plant/Equipment, Total - Gross | 2.59 | 2.6 | 4.326 | 4.641 | 4.706 |
Accumulated Depreciation, Total | -1.711 | -1.471 | -3.602 | -3.914 | -3.57 |
Other Long Term Assets, Total | 1.536 | 0.875 | 1.554 | 1.225 | 1.816 |
Total Current Liabilities | 5.819 | 4.078 | 4.729 | 3.591 | 3.261 |
Accounts Payable | 1.641 | 1.769 | 2.067 | 1.255 | 1.272 |
Accrued Expenses | 1.309 | 1.027 | 1.446 | 1.236 | 1.023 |
Notes Payable/Short Term Debt | 0.688 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0.12 | 0.596 | 0.481 | 0.463 | 0.377 |
Other Current Liabilities, Total | 2.061 | 0.686 | 0.735 | 0.637 | 0.589 |
Total Liabilities | 10.148 | 9.624 | 8.937 | 3.959 | 3.88 |
Total Long Term Debt | 0 | 1.31 | 0 | 0.012 | 0.176 |
Long Term Debt | 0 | 1.31 | 0 | 0.012 | 0.032 |
Capital Lease Obligations | 0 | 0.144 | |||
Other Liabilities, Total | 4.329 | 4.236 | 4.208 | 0.356 | 0.443 |
Total Equity | 8.697 | 5.363 | 5.624 | 10.489 | 15.326 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.002 | 0.002 | 0.002 | 0.002 | 0.001 |
Additional Paid-In Capital | 197.37 | 189.217 | 186.559 | 184.074 | 176.74 |
Retained Earnings (Accumulated Deficit) | -184.363 | -179.277 | -175.327 | -169.238 | -157.44 |
Other Equity, Total | -4.312 | -4.579 | -5.61 | -4.349 | -3.975 |
Total Liabilities & Shareholders’ Equity | 18.845 | 14.987 | 14.561 | 14.448 | 19.206 |
Total Common Shares Outstanding | 3.10094 | 2.09291 | 1.77748 | 1.31634 | 0.68575 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
流动资产总额 | 11.232 | 12.393 | 14.817 | 16.43 | 17.699 |
现金和短期投资 | 2.634 | 3.351 | 5.586 | 7.396 | 8.529 |
现金等价物 | 2.634 | 3.351 | 5.586 | 7.396 | 8.529 |
应收账款总额,净额 | 2.297 | 2.487 | 2.434 | 2.407 | 2.854 |
Accounts Receivable - Trade, Net | 2.297 | 2.487 | 2.434 | 2.407 | 2.854 |
Total Inventory | 2.849 | 3.025 | 2.788 | 2.663 | 2.879 |
Prepaid Expenses | 3.23 | 3.315 | 3.794 | 3.746 | 3.226 |
Other Current Assets, Total | 0.222 | 0.215 | 0.215 | 0.218 | 0.211 |
Total Assets | 13.928 | 14.962 | 17.158 | 18.845 | 19.347 |
Property/Plant/Equipment, Total - Net | 0.785 | 0.835 | 0.787 | 0.879 | 0.922 |
Other Long Term Assets, Total | 1.911 | 1.734 | 1.554 | 1.536 | 0.726 |
Total Current Liabilities | 3.934 | 3.527 | 4.854 | 5.819 | 3.875 |
Accounts Payable | 1.302 | 1.074 | 2.057 | 1.641 | 1.583 |
Accrued Expenses | 2.477 | 2.071 | 2.185 | 2.093 | 1.553 |
Notes Payable/Short Term Debt | 0 | 0.229 | 0.459 | 0.688 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 0 | 0 | 0.12 | 0.587 |
Other Current Liabilities, Total | 0.155 | 0.153 | 0.153 | 1.277 | 0.152 |
Total Liabilities | 8.369 | 7.941 | 9.199 | 10.148 | 8.178 |
Total Long Term Debt | 0.015 | 0.015 | 0.015 | 0 | 0 |
Long Term Debt | 0.015 | 0.015 | 0.015 | 0 | 0 |
Other Liabilities, Total | 4.42 | 4.399 | 4.33 | 4.329 | 4.303 |
Total Equity | 5.559 | 7.021 | 7.959 | 8.697 | 11.169 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.002 | 0.002 | 0.002 | 0.002 | 0.003 |
Additional Paid-In Capital | 197.939 | 197.697 | 197.584 | 197.37 | 197.156 |
Retained Earnings (Accumulated Deficit) | -188.206 | -186.267 | -185.25 | -184.363 | -181.419 |
Other Equity, Total | -4.176 | -4.411 | -4.377 | -4.312 | -4.571 |
Total Liabilities & Shareholders’ Equity | 13.928 | 14.962 | 17.158 | 18.845 | 19.347 |
Total Common Shares Outstanding | 3.10965 | 3.10297 | 3.10094 | 3.10094 | 3.09934 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
净收入/起跑线 | -5.086 | -3.95 | -2.946 | -11.798 | -14.328 |
经营活动产生的现金 | -4.248 | -3.378 | -4.591 | -11.717 | -12.439 |
经营活动产生的现金 | 0.186 | 0.227 | 0.312 | 0.453 | 0.49 |
非现金物品 | -1.873 | -1.039 | -0.398 | 0.894 | 3.151 |
已付现金利息 | 0.024 | 0.012 | 0.016 | 0.033 | 0.04 |
营运资金的变化 | 3.354 | 1.384 | -1.559 | -1.266 | -1.752 |
投资活动产生的现金 | -0.099 | 0.388 | 3.644 | -0.131 | -0.201 |
资本支出 | -0.137 | -0.179 | -0.206 | -0.1 | -0.187 |
其他投资现金流量项目,总计 | 0.038 | 0.567 | 3.85 | -0.031 | -0.014 |
融资活动产生的现金 | 7.396 | 3.308 | 1.029 | 5.492 | 5.24 |
股票的发行(报废),净额 | 7.77 | 2.287 | 1.376 | 5.97 | 5.52 |
债务的发行(退还),净额 | -0.374 | 1.021 | -0.347 | -0.478 | -0.28 |
外汇效应 | 0.127 | 0.211 | -0.08 | -0.021 | 0.005 |
现金净变化 | 3.176 | 0.529 | 0.002 | -6.377 | -7.395 |
Cash Taxes Paid | 0.767 | 0.941 | |||
Deferred Taxes | -0.829 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -3.843 | -1.904 | -0.887 | -5.086 | -2.142 |
Cash From Operating Activities | -3.711 | -3.363 | -1.533 | -4.248 | -2.853 |
Cash From Operating Activities | 0.091 | 0.059 | 0.031 | 0.186 | 0.137 |
Non-Cash Items | 0.568 | 0.327 | 0.214 | -1.873 | -0.703 |
Cash Interest Paid | 0.012 | 0.008 | 0.004 | 0.024 | 0.012 |
Changes in Working Capital | -0.284 | -1.706 | -0.851 | 3.354 | -0.145 |
Cash From Investing Activities | -0.176 | -0.21 | -0.023 | -0.099 | -0.038 |
Capital Expenditures | -0.079 | -0.048 | -0.023 | -0.137 | -0.075 |
Other Investing Cash Flow Items, Total | -0.097 | -0.162 | 0.038 | 0.037 | |
Cash From Financing Activities | -0.883 | -0.565 | -0.387 | 7.396 | 7.174 |
Issuance (Retirement) of Stock, Net | 0 | 0 | 7.77 | 7.77 | |
Issuance (Retirement) of Debt, Net | -0.794 | -0.565 | -0.35 | -0.374 | -0.596 |
Foreign Exchange Effects | 0.008 | 0.093 | 0.133 | 0.127 | 0.026 |
Net Change in Cash | -4.762 | -4.045 | -1.81 | 3.176 | 4.309 |
Financing Cash Flow Items | -0.089 | -0.037 | |||
Deferred Taxes | -0.243 | -0.139 | -0.04 | -0.829 | |
Cash Taxes Paid | 0.055 |
投资者名称 | 投资者类型 | 流通股百分比 | 持有股份 | 股份变动 | 持有日期 | 换手率 |
---|---|---|---|---|---|---|
Renaissance Technologies LLC | Hedge Fund | 0.9027 | 41967 | -32500 | 2023-03-31 | HIGH |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7789 | 36214 | -541 | 2023-03-31 | LOW |
Millennium Management LLC | Hedge Fund | 0.507 | 23574 | 6974 | 2023-03-31 | HIGH |
Virtu Americas LLC | Research Firm | 0.3456 | 16068 | 16068 | 2023-03-31 | HIGH |
Ground Swell Capital, LLC | Investment Advisor | 0.2867 | 13329 | 13329 | 2023-03-31 | HIGH |
Tower Research Capital LLC | Hedge Fund | 0.1845 | 8580 | 520 | 2023-03-31 | HIGH |
Birnbaum (Jay E) | Individual Investor | 0.1234 | 5739 | 0 | 2022-07-22 | |
McLaughlin (Jerry G.) | Individual Investor | 0.1164 | 5414 | 0 | 2022-07-22 | |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.0618 | 2875 | 0 | 2023-03-31 | LOW |
Advisory Services Network, LLC | Investment Advisor | 0.053 | 2463 | 2463 | 2023-03-31 | LOW |
Thornton (Bruce) | Individual Investor | 0.0177 | 825 | 0 | 2022-07-22 | |
JPMorgan Private Bank (United States) | Bank and Trust | 0.0145 | 672 | 672 | 2023-03-31 | LOW |
U.S. Bancorp Asset Management, Inc. | Investment Advisor | 0.0108 | 500 | 0 | 2023-03-31 | LOW |
Advisor Group, Inc | Investment Advisor | 0.0046 | 216 | 50 | 2023-03-31 | LOW |
Morgan Stanley Smith Barney LLC | Investment Advisor | 0.0018 | 86 | 0 | 2023-03-31 | LOW |
Allworth Financial, L.P. | Investment Advisor | 0.0014 | 65 | 0 | 2023-03-31 | LOW |
BofA Global Research (US) | Research Firm | 0.0009 | 44 | 0 | 2023-03-31 | LOW |
Gradient Investments LLC | Investment Advisor | 0.0007 | 31 | 0 | 2023-03-31 | MED |
Wells Fargo Bank, N.A. | Bank and Trust | 0.0005 | 21 | 0 | 2023-03-31 | LOW |
NewSquare Capital LLC | Investment Advisor | 0.0002 | 10 | 0 | 2023-03-31 | MED |
交易计算器
如果您在特定日期(选择一个日期)开立差价合约交易并在不同日期(选择一个日期)关闭交易,计算您的假设盈亏。
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Sonoma Pharma Company profile
关于 Sonoma Pharma
Sonoma Pharmaceuticals, Inc.从事开发和生产次氯酸(HOCl)产品,其应用范围包括伤口护理、动物保健、眼睛护理、口腔护理和皮肤病。 该公司的产品包括Epicyn抗菌洁面乳、Levicyn抗菌皮肤喷雾剂、Levicyn止痒凝胶、Levicyn止痒喷雾凝胶、Celacyn疤痕管理凝胶和Sebuderm外用凝胶。 其产品主要针对痤疮的治疗、疤痕管理和特应性皮炎。 它还有办公室配药产品,如Lasercyn Dermal Spray、Lasercyn Post Procedure Gel和Regenacyn Advanced Scar Management。 该公司直接或通过合作伙伴在全球约54个国家销售其产品。 其子公司包括Aquamed Technologies, Inc., Oculus Technologies of Mexico, S.A. de C.V. 和Sonoma Pharmaceuticals Netherlands B.V.。
Industry: | Pharmaceuticals (NEC) |
5445 Conestoga Court, Suite 150
BOULDER
COLORADO 80301
US
收入报表
- Annual
- Quarterly
人们也观看
还在找一位您可以信任的经纪商吗?
加入成为全球535,000万多名交易者的一份子,选择利用Capital.com进行交易吧。